SRR8518400
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.420
- IL6_JAK_STAT3_SIGNALING+0.380
- INFLAMMATORY_RESPONSE+0.370
- INTERFERON_GAMMA_RESPONSE+0.320
- TNFA_SIGNALING_VIA_NFKB+0.290
- KRAS_SIGNALING_UP+0.270
- APOPTOSIS+0.260
- PROTEIN_SECRETION+0.240
- COMPLEMENT+0.220
- IL2_STAT5_SIGNALING+0.190
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- HEDGEHOG_SIGNALING-0.300
- HYPOXIA-0.300
- NOTCH_SIGNALING-0.300
- ANGIOGENESIS-0.280
- MYC_TARGETS_V2-0.280
- APICAL_JUNCTION-0.240
- GLYCOLYSIS-0.230
- ESTROGEN_RESPONSE_EARLY-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ff12dc45-d7ab-45ae-a049-2d20e3c546b6 | — | — | 0.830 |
| 2 | 20090401.Her2HRpos | — | D | 0.819 |
| 3 | SRR8518312 | — | D | 0.814 |
| 4 | SAMN03290949 | — | — | 0.814 |
| 5 | SRR8518386 | — | D | 0.792 |
| 6 | SRR8518384 | — | D | 0.792 |
| 7 | BSR_02_0049_A5_S69 | — | D | 0.785 |
| 8 | 9bc1133d-a577-4f31-bf6b-50748c60da80 | — | — | 0.781 |
| 9 | 20110002.Her2HRneg | — | D | 0.777 |
| 10 | ERR2208965 | — | — | 0.771 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.180 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.160 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.130 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| COAGULATION | 0.110 | Binimetinib | — uncovered |
| E2F_TARGETS | 0.090 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| G2M_CHECKPOINT | 0.070 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.050 | Idelalisib | — uncovered |